{"nctId":"NCT00390910","briefTitle":"Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants","startDateStruct":{"date":"2006-10-01","type":"ACTUAL"},"conditions":["Infections, Streptococcal"],"count":286,"armGroups":[{"label":"Synflorix™ + Infanrix™ hexa Group I","type":"EXPERIMENTAL","interventionNames":["Biological: Pneumococcal conjugate vaccine GSK1024850A","Biological: Infanrix hexa"]},{"label":"Synflorix™ + Infanrix™ hexa Group II","type":"EXPERIMENTAL","interventionNames":["Biological: Pneumococcal conjugate vaccine GSK1024850A","Biological: Infanrix hexa"]},{"label":"Synflorix™ + Infanrix™ hexa Group III","type":"EXPERIMENTAL","interventionNames":["Biological: Pneumococcal conjugate vaccine GSK1024850A","Biological: Infanrix hexa"]}],"interventions":[{"name":"Pneumococcal conjugate vaccine GSK1024850A","otherNames":[]},{"name":"Infanrix hexa","otherNames":["DTPa-HBV-IPV/Hib"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol\n* A male or female between, and including, 8-16 weeks (56-118 days) of age at the time of the first vaccination.\n* Written informed consent obtained from the parent or guardian of the subject.\n* Born after a gestation period of \\>27 weeks (at least 189 days).\n* If full term born, healthy subjects as established by medical history and clinical examination before entering into the study\n* If premature, medically stable condition (not requiring significant medical support or ongoing management for debilitating disease and having demonstrated a clinical course of sustained recovery).\n\nExclusion Criteria:\n\n* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccines, or planned use during the study period\n* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs from birth to the first vaccine dose.\n* Planned administration/administration of a vaccine not foreseen by the study protocol, during the period starting from one month before the first dose of vaccines and up to Visit 6.\n* Previous vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, Neisseria meningitidis and/or Streptococcus pneumoniae with the exception of vaccines where the first dose can be given within the first two weeks of life according to the national recommendations\n* History of or intercurrent diphtheria, tetanus, pertussis, hepatitis B, polio, Haemophilus influenzae type b disease, Neisseria meningitidis.\n* History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.\n* History of any neurologic disorders or seizures (this criterion does not apply to subjects who have had a single, uncomplicated febrile convulsion in the past).\n* Acute disease at the time of enrolment.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination\n* A family history of congenital or hereditary immunodeficiency.\n* Major congenital defects or serious chronic illness.\n* Administration of immunoglobulins, with the exception of monoclonal antibodies against RSV, and/or any blood products within one month preceding the first dose of study vaccines or planned administration during the active phase of the study.","healthyVolunteers":true,"sex":"ALL","minimumAge":"8 Weeks","maximumAge":"16 Weeks","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With Core Fever (Rectal Temperature) Greater Than (>) the Cut-off","description":"Fever was measured as rectal temperature. Assessment of occurrences of fever \\> 39.0 °C was performed post doses 1, 2 and 3 of Synflorix or Infanrix hexa vaccine.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any and Grade 3 Solicited Local Symptoms","description":"Solicited local symptoms assessed included pain, redness and swelling. Grade 3 pain was defined as crying when limb was moved/ spontaneously painful. Grade 3 swelling/ redness was defined as swelling/ redness greater than (\\>) 30 millimeters (mm). \"Any\" was defined as incidence of the specified symptom regardless of intensity.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any and Grade 3 Solicited General Symptoms","description":"Solicited general symptoms assessed included drowsiness, fever (defined as rectal temperature ≥ 38.0°C), irritability, and loss of appetite. Grade 3 drowsiness was defined as drowsiness which prevented normal everyday activities. Grade 3 fever was defined as fever (rectal temperature) above (\\>) 40.0 degree Celsius (°C). Grade 3 irritability was defined as crying that could not be comforted/ preventing normal activity. Grade 3 loss of appetite was defined as the subject not eating at all. \"Any\" was defined as incidence of the specified symptom regardless of intensity or relationship to study vaccination.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Unsolicited Adverse Events (AEs)","description":"An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. \"Any\" was defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Serious Adverse Events (SAEs)","description":"Serious adverse events (SAEs) assessed included medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/ incapacity.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Serious Adverse Events (SAEs)","description":"Serious adverse events (SAEs) assessed included medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/ incapacity.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Greater Than or Equal to (≥) the Cut-off","description":"The cut-off for the assay was ≥ 0.20 microgram per mililiter (μg/ mL).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"82","spread":null},{"groupId":"OG002","value":"129","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"81","spread":null},{"groupId":"OG002","value":"130","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"82","spread":null},{"groupId":"OG002","value":"129","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"78","spread":null},{"groupId":"OG002","value":"123","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"82","spread":null},{"groupId":"OG002","value":"131","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"82","spread":null},{"groupId":"OG002","value":"132","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"82","spread":null},{"groupId":"OG002","value":"132","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"81","spread":null},{"groupId":"OG002","value":"130","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"82","spread":null},{"groupId":"OG002","value":"132","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"79","spread":null},{"groupId":"OG002","value":"125","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F ≥ the Cut-off","description":"The cut-off for the assay was ≥ 0.05 microgram per mililiter (μg/mL).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"82","spread":null},{"groupId":"OG002","value":"130","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"82","spread":null},{"groupId":"OG002","value":"130","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"82","spread":null},{"groupId":"OG002","value":"129","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"81","spread":null},{"groupId":"OG002","value":"131","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"82","spread":null},{"groupId":"OG002","value":"131","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"82","spread":null},{"groupId":"OG002","value":"132","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"82","spread":null},{"groupId":"OG002","value":"132","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"81","spread":null},{"groupId":"OG002","value":"131","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"82","spread":null},{"groupId":"OG002","value":"132","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"81","spread":null},{"groupId":"OG002","value":"129","spread":null}]}]}]},{"type":"SECONDARY","title":"Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F","description":"Seropositivity status, defined as anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations ≥ 0.05 microgram per milliliter (μg/mL).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.97","spread":null},{"groupId":"OG001","value":"1.1","spread":null},{"groupId":"OG002","value":"1.35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.53","spread":null},{"groupId":"OG001","value":"1.88","spread":null},{"groupId":"OG002","value":"2.42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.45","spread":null},{"groupId":"OG001","value":"1.93","spread":null},{"groupId":"OG002","value":"2.31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.85","spread":null},{"groupId":"OG001","value":"1.11","spread":null},{"groupId":"OG002","value":"1.18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.87","spread":null},{"groupId":"OG001","value":"2.37","spread":null},{"groupId":"OG002","value":"2.69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.43","spread":null},{"groupId":"OG001","value":"1.69","spread":null},{"groupId":"OG002","value":"2.41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.52","spread":null},{"groupId":"OG001","value":"3.28","spread":null},{"groupId":"OG002","value":"3.71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.28","spread":null},{"groupId":"OG001","value":"4.86","spread":null},{"groupId":"OG002","value":"5.22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":null},{"groupId":"OG001","value":"4.8","spread":null},{"groupId":"OG002","value":"4.56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.05","spread":null},{"groupId":"OG001","value":"1.33","spread":null},{"groupId":"OG002","value":"1.54","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F ≥ the Cut-off","description":"The cut-off for the assay was ≥ 8","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"49","spread":null},{"groupId":"OG002","value":"80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"72","spread":null},{"groupId":"OG002","value":"110","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"69","spread":null},{"groupId":"OG002","value":"104","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"59","spread":null},{"groupId":"OG002","value":"85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"74","spread":null},{"groupId":"OG002","value":"113","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"72","spread":null},{"groupId":"OG002","value":"103","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"73","spread":null},{"groupId":"OG002","value":"110","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"65","spread":null},{"groupId":"OG002","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"71","spread":null},{"groupId":"OG002","value":"105","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"70","spread":null},{"groupId":"OG002","value":"109","spread":null}]}]}]},{"type":"SECONDARY","title":"Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F","description":"Seropositivity status, defined as Opsonophagocytic activity against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F ≥ 8.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"30.3","spread":null},{"groupId":"OG002","value":"46.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"644.1","spread":null},{"groupId":"OG001","value":"500.9","spread":null},{"groupId":"OG002","value":"543.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.2","spread":null},{"groupId":"OG001","value":"70.8","spread":null},{"groupId":"OG002","value":"94.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"278.3","spread":null},{"groupId":"OG001","value":"305.1","spread":null},{"groupId":"OG002","value":"268.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4086.3","spread":null},{"groupId":"OG001","value":"3047.3","spread":null},{"groupId":"OG002","value":"2395.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"930.5","spread":null},{"groupId":"OG001","value":"837.9","spread":null},{"groupId":"OG002","value":"1144.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"775.4","spread":null},{"groupId":"OG001","value":"901.6","spread":null},{"groupId":"OG002","value":"644.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"262.5","spread":null},{"groupId":"OG001","value":"321.5","spread":null},{"groupId":"OG002","value":"251","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104.2","spread":null},{"groupId":"OG001","value":"201.1","spread":null},{"groupId":"OG002","value":"182.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1659.4","spread":null},{"groupId":"OG001","value":"1147.2","spread":null},{"groupId":"OG002","value":"1558.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Concentrations of Antibodies Against Cross-reactive Pneumococcal Serotypes 6A and 19A ≥ the Cut-off","description":"The cut-off for the assay was ≥ 0.05 microgram per milliliter (μg/mL).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"68","spread":null},{"groupId":"OG002","value":"114","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"72","spread":null},{"groupId":"OG002","value":"120","spread":null}]}]}]},{"type":"SECONDARY","title":"Concentrations of Antibodies Against Cross-reactive Pneumococcal Serotypes 6A and 19A","description":"Seropositivity status was defined as anti-pneumococcal cross-reactive serotypes 6A and 19A antibody concentrations ≥ 0.05 microgram per milliliter (μg/mL).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":null},{"groupId":"OG001","value":"0.21","spread":null},{"groupId":"OG002","value":"0.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":null},{"groupId":"OG001","value":"0.21","spread":null},{"groupId":"OG002","value":"0.26","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes 6A and 19A ≥ the Cut-off","description":"The cut-off for the assay was ≥ 8.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"54","spread":null},{"groupId":"OG002","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes 6A and 19A","description":"Seropositivity status was defined as opsonophagocytic activity against pneumococcal cross-reactive serotypes 6A and 19A ≥ 8.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"114.5","spread":null},{"groupId":"OG001","value":"157.3","spread":null},{"groupId":"OG002","value":"49.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":null},{"groupId":"OG001","value":"7.1","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Concentrations of Antibodies Against Protein D (Anti-PD) ≥ the Cut-off","description":"The cut-off for the assay was ≥ 100 enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"82","spread":null},{"groupId":"OG002","value":"130","spread":null}]}]}]},{"type":"SECONDARY","title":"Concentrations of Antibodies Against Protein D (Anti-PD)","description":"Seropositivity status was defined as anti-PD antibody concentrations ≥ 100 ELISA units per milliliter ( EL.U/mL).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1688.6","spread":null},{"groupId":"OG001","value":"1415.4","spread":null},{"groupId":"OG002","value":"1496.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-diphtheria (Anti DT) and Anti-tetanus Toxoids (Anti TT) Antibody Concentrations ≥ the Cut-off","description":"The cut-off for the assay was ≥ 0.1 international units per milliliter (IU/mL).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"61","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody Concentrations for Anti-diphtheria and Tetanus Toxoids ≥ the Cut-off","description":"Seroprotection status was defined as anti-diphtheria toxoid or anti-tetanus toxoid antibody concentrations ≥ 0.1 IU/mL","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.495","spread":null},{"groupId":"OG001","value":"3.23","spread":null},{"groupId":"OG002","value":"3.077","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.745","spread":null},{"groupId":"OG001","value":"8.617","spread":null},{"groupId":"OG002","value":"7.695","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration ≥ the Cut-off","description":"The cut-off for the assay was ≥ 0.15 microgram per milliliter (μg/mL).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"63","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration ≥ the Cut-off","description":"The cut-off for the assay was ≥ 1.0 microgram per milliliter (μg/mL).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"38","spread":null},{"groupId":"OG002","value":"60","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-polyribosyl-ribitol-phosphate (Anti-PRP) Antibody Concentrations ≥ th Cut-off","description":"Seroprotection status was defined as anti-PRP antibody concentrations ≥ 0.15 μg/mL and ≥ 1.0 μg/mL","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.031","spread":null},{"groupId":"OG001","value":"5.804","spread":null},{"groupId":"OG002","value":"7.952","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations ≥ the Cut-off","description":"The cut-off for the assay was ≥ 5 ELISA unit per milliliter (EL.U/mL).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"60","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody Concentration for Anti-pertussis Toxoid (Anti-PT) , Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN)","description":"Seropositivity status was defined as anti-PT, anti-FHA, anti-PRN antibody concentrations ≥ 5 EL.U/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.9","spread":null},{"groupId":"OG001","value":"37.9","spread":null},{"groupId":"OG002","value":"47.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"188.6","spread":null},{"groupId":"OG001","value":"169","spread":null},{"groupId":"OG002","value":"163.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"127.6","spread":null},{"groupId":"OG001","value":"109.1","spread":null},{"groupId":"OG002","value":"119.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-Hepatitis B Surface Antigen (HBs) Antibody Concentrations ≥ the Cut-off.","description":"The cut-off for the assay was ≥ 10 milli-international units per milliliter (mIU/mL).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-hepatitis B Surface Antigen (HBs) Antibody Concentrations","description":"Seroprotection status was defined as Anti-HBs antibody concentrations ≥ 10 mIU/mL","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"431.9","spread":null},{"groupId":"OG001","value":"356","spread":null},{"groupId":"OG002","value":"462.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-polio Type 1, 2 and 3 Antibody Titres","description":"The cut-off for the assay was ≥ 8.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"21","spread":null},{"groupId":"OG002","value":"29","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody Titers for Polio Type 1, 2 and 3 ≥ the Cut-off","description":"Seroprotection status was defined as Anti-polio type 1, Anti-polio type 2 and Anti-polio type 3 antibody titers ≥ 8.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"271.3","spread":null},{"groupId":"OG001","value":"189.5","spread":null},{"groupId":"OG002","value":"230.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"341.7","spread":null},{"groupId":"OG001","value":"319","spread":null},{"groupId":"OG002","value":"194.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"248.4","spread":null},{"groupId":"OG001","value":"344.7","spread":null},{"groupId":"OG002","value":"384.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Vaccine Response to Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN)","description":"Vaccine response to PT, FHA and PRN was defined as appearance of antibodies in subjects who are initially seronegative (S-), or at least maintenance of pre-vaccination antibody concentrations in those who are initially seropositive (S+). For the SYNFLORIX™ + INFANRIX™ HEXA GROUP I, no subjects presented initial seropositivity for PT and PRN antigens.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"34","spread":null},{"groupId":"OG002","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":17,"n":50},"commonTop":["Erythema","Irritability","Swelling","Pain","Pyrexia"]}}}